ClinicalTrials.gg
CompletedNCT05730842Updated Apr 18, 2023

Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers

A Phase 1 interventional study of EDG-5506 Tablet and Radiolabeled EDG-5506 Suspension in Healthy Volunteer, Muscular Dystrophies and Muscular Disorders, Atrophic, sponsored by Edgewise Therapeutics, Inc.. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-18.

Sponsored by Edgewise Therapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2023, 3 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies in Muscular Dystrophies with a site in United States — 32 open to participants now, 43 under way, 2 of them phase 3. Muscular Dystrophies · United States.

Enrollment
58th of 80
15 · median 41
Started
2023
with 9 others
Phase 1
15 of 127
1 open now
Registered
100th of 127
by date

Among the 127 studies in Muscular Dystrophies with a site in United States, this one is the 58th largest by enrollment of the 80 interventional ones that give a count, is one of 10 that started in 2023, is one of 15 in phase 1, and was the 100th registered.

Muscular Dystrophies

224 studies on the registry are indexed under Muscular Dystrophies; 48 are open to participants now.

Browse Muscular Dystrophies studies →

Open to participants now

32 of the 127 studies in Muscular Dystrophies with a site in United States are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Muscular Dystrophies studies recruiting now, 14 (37%) set no upper age limit and 15 (39%) stop at 75 or younger; 24 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Muscular Dystrophies with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1 2-part, single-center, open-label study in healthy male volunteers. Part A will assess the absorption, metabolism, excretion, and pharmacokinetics of one oral dose of radiolabeled EDG-5506. Part B will assess bioavailability of EDG-5506 with a single oral dose of EDG-5506 and a single intravenous dose of radiolabeled EDG-5506.

Read the detailed description

This is a Phase 1 2-part, single-center, open-label study.

Up to 15 (8 in Part A and 7 in Part B) healthy male subjects will be enrolled in the study.

Part A:

Potential subjects will be screened to assess eligibility within 28 days prior to dose administration. Subjects will be admitted on Day -1 and confined to the study site until at least Day 30. On Day 1, subjects will receive a single oral suspension. Blood, urine and feces samples will be collected for determination of EDG-5506 concentration, total radioactivity, and metabolite profiling and identification. Between Day 30 and Day 36, subjects will be discharged.

Part B:

Potential subjects will be screened to assess their eligibility within 42 days prior to dose administration. Subjects will be admitted on Day -1 and confined to the study site until Day 8. On Day 1, subjects will receive a single oral dose of EDG-5506 in the fasted state followed 2 hours later by a single dose of radiolabeled EDG-5506. Subjects will be discharged from the study site on Day 8. Blood samples will be collected.

03

Conditions studied

  • Healthy Volunteer
  • Muscular Dystrophies
  • Muscular Disorders, Atrophic
  • Muscular Diseases
  • Musculoskeletal Diseases
  • Neuromuscular Diseases
  • Nervous System Diseases
  • Genetic Diseases, Inborn

Keywords

  • Healthy Volunteer
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. For both Part A and Part B, males, of any race, between 18 and 55 years of age, inclusive.
  2. For both Part A and Part B, a between 18.0 and 32.0 kg/m2, inclusive, and a total body weight greater than or equal to 50 kg.
  3. In good health, determined by no findings from medical history, 12-lead , vital signs measurements, and clinical laboratory evaluations at screening and check-in.

Exclusion criteria

Exclusion Criteria:

  1. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, genitourinary, immunological, or psychiatric disorder, as determined by the investigator (or designee).
  2. Participation in a clinical study involving administration of an drug in the past 30 days or 5 half-lives (whichever is longer) prior to dosing.
  3. Participation in more than 3 radiolabeled drug studies in the last 12 months.
  4. Poor peripheral venous access.
  5. Subjects with exposure to significant diagnostic or therapeutic radiation (eg, serial x-ray, computed tomography scan, barium meal) or current employment in a job requiring radiation exposure monitoring within 12 months prior to check-in.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Part A - AME

    Evaluation of absorption, metabolism, excretion and pharmacokinetics of a single oral dose of radiolabeled EDG-5506 in healthy male volunteers

    Drug: Radiolabeled EDG-5506 Suspension

  • Experimental
    Part B - aBA

    Evaluation of bioavailability of a single oral dose of EDG-5506 followed by a single intravenous dose of radiolabeled EDG-5506 in healthy male volunteers

    Drug: EDG-5506 Tablet · Drug: Radiolabeled EDG-5506 Intravenous

Interventions

  • Single Oral Dose - Tablet

  • DrugRadiolabeled EDG-5506 Suspension

    Single Oral Dose

  • DrugRadiolabeled EDG-5506 Intravenous

    Single Intravenous Dose

06

What researchers measure

Primary outcomes

  1. The mass balance of EDG-5506 as measured by the total radioactivity recovered in urine

    Time frame: Up to 37 days

  2. The mass balance of EDG-5506 as measured by the total radioactivity recovered in feces

    Time frame: Up to 37 days

  3. Plasma maximum measured drug concentration (Cmax) measurements for EDG-5506

    Time frame: Up to 37 days

  4. Characterization of EDG-5506 as measured by urinary recovery (fet1-t2)

    Time frame: Up to 37 days

  5. Absolute bioavailability of EDG-5506 as measured by Fabs

    Time frame: Up to 9 days

Secondary outcomes

  1. Incidence of treatment-emergent adverse events

    Time frame: Up to 37 days

  2. Incidence of abnormal clinical laboratory test results

    Time frame: Up to 37 days

  3. Incidence of abnormal electrocardiograms (ECGs)

    Time frame: Up to 37 days

  4. Distribution of total radioactivity into blood cells as measured by whole blood to plasma concentration ratio

    Time frame: Up to 37 days

07

Study locations

1 site
  • Labcorp Clinical Research Unit, Inc.
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Apr 2023, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2023
First posted
Feb 16, 2023
StartActual
Jan 12, 2023
Primary completionActual
Apr 6, 2023
CompletionActual
Apr 6, 2023
Last update
Apr 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05730842
Lead sponsor
Edgewise Therapeutics, Inc.
Responsible party
Sponsor
First posted
Feb 16, 2023
Start date
Jan 12, 2023
Primary completion
Apr 6, 2023
Completion
Apr 6, 2023
Last update
Apr 18, 2023

Study contacts

Sam Collins, MBBS, PhD
study chair · Edgewise Therapeutics, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sevasemten

Start the discussion